TVTX Q4 2017 Earnings — Travere Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

TVTXTravere Therapeutics, Inc.

$3B

Q4 2017 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$42M+13.0% YoY

Gross Profit

$41M97.2% margin

Operating Income

-$15M-36.0% margin

Net Income

-$18M-41.8% margin

EPS (Diluted)

$-0.44

QoQ Revenue Growth

+4.6%

Cash Flow

Operating Cash Flow

-$854,000

Free Cash Flow

-$4M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$520M

Total Liabilities

$227M

Stockholders' Equity

$293M

Cash & Equivalents

$99M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$42M	$37M	+13.0%
Gross Profit	$41M	$36M	+13.5%
Operating Income	-$15M	-$18M	+16.7%
Net Income	-$18M	-$9M	-104.8%